Stemline Therapeutics Lands $33,000,000 New Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=2eba4bd8-cf8c-4dc1-8246-70998512967f&Preview=1 -
Date
1/29/2013 -
Company Name
Stemline Therapeutics -
Mailing Address
1675 York Ave New York, NY 10128 -
Company Description
Stemline Therapeutics, Inc. (NASDAQ: STML) is a clinical stage biotechnology company developing oncology compounds directed to cancer stem cell targets. Stemline’s lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I human trial. Behind its lead, Stemline is developing a pipeline of small molecule and biologic compounds directed at additional cancer stem cell targets of a variety of solid and hematological cancers. -
Website
http://www.stemline.com -
Transaction Type
IPO -
Transaction Amount
$33,000,000 -
Transaction Round
Undisclosed -
Proceeds Purposes
Proceeds purposes are on file with company statements at the SEC. -
M&A Terms
